Neurocrine (NBIX) Q2 2026 Earnings Call Transcript
Thursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Todd Tushla Chief Executive Officer - Kyle W. Gano Chief Financial Officer - Matthew Abernethy Chief Commercial Officer - Eric S. Benevich Chief Medical Officer - Sanjay Keswani Chief Business Officer - Samir Siddhanti Need a quote from a Motley Fool analyst?
How this was made
The 30-second read
Why it matters
Key trading inputs are the raised INGREZZA annual guidance, reported Q2 financials (revenue and non-GAAP EPS), and portfolio expansion metrics (CRENESSITY penetration/prescriber growth and VYKAT XR pro forma/recognized revenue). Management also reiterates 2H 2027 Phase 3 timelines and discusses IRA implementation timing (target 2029).
Market read
This call provides concrete guidance and portfolio performance metrics that can drive near-term earnings estimate revisions and sentiment, while also setting expectations for major clinical readouts in 2H 2027.
What to watch
The excerpt highlights IRA Maximum Fair Price discussions and potential 2029 EPS variability, which could pressure longer-duration valuation even if 2026-2027 execution looks strong.
Background
Neurocrine describes a transition to a multiproduct commercial stage company after integrating Soleno Therapeutics, alongside ongoing rare-disease and psychiatry development.
Ticker impact
Neurocrine reported Q2 2026 revenue of $950M and raised INGREZZA annual guidance to $2.825B-$2.875B based on first-half performance.
Likely positive bias for near-term trading as guidance is increased and cash balance/debt-free status reduces balance-sheet risk; upside may be tempered by long-dated 2027 Phase 3 timelines.
The article discloses specific, decision-relevant numbers (revenue, non-GAAP EPS, and raised annual guidance) and concrete acquisition/portfolio metrics, which typically drive earnings revisions and sentiment. However, it is a transcript and the excerpt does not include consensus or market reaction, limiting precision on magnitude.
Market effects
Reinforces investor focus on rare-disease commercial execution and pipeline read-through into 2027 Phase 3 psychiatry and endocrinology catalysts.
Primarily US-focused biotech sentiment via Medicare IRA discussion and US payer coverage metrics.
Limited direct global read-through in the excerpt beyond rare-disease commercialization and clinical development timelines.
Counterpoint
The guidance raise may already reflect known demand trends, while the biggest value inflection points (direclidine and osavampator Phase 3 readouts) are still 2H 2027, leaving near-term upside dependent on continued prescriber growth.
Key entities
- companyNeurocrine Biosciences
Reported Q2 2026 results, raised INGREZZA annual guidance, and outlined 2027 Phase 3 clinical catalysts and IRA-related pricing timeline.
- productINGREZZA
Lead asset with Q2 net sales of $716M and raised annual guidance to $2.825B-$2.875B.
- productCRENESSITY
Rare-disease therapy with $184M net sales and 15% market penetration within six quarters of launch.
- productVYKAT XR
Prader-Willi syndrome treatment with $94M pro forma sales and $54M recognized revenue post-acquisition close.
- acquisitionSoleno Therapeutics
Acquired for $2.9B cash, described as expanding rare disease and endocrinology portfolios.
